Approval · Notice of Compliance 6002 · 2004
ANDRODERM: Notice of Compliance 6002
Issued December 13, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 6002
- Date
- December 13, 2004
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph
- Therapeutic class
- Testosterone replacement therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ANDRODERM | Not yet assigned | — |
Medicinal ingredients
- TESTOSTERONE 12.2 MG per PAD
- TESTOSTERONE 24.3 MG per PAD